The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer
Abstract
On December 19, 2016, the FDA granted accelerated approval to rucaparib (RUBRACA; Clovis Oncology, Inc.) for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)–associated advanced ovarian cancer who have been treated with two or more chemotherapies. The FDA also approved the FoundationFocus CDxBRCA test (Foundation Medicine, Inc.), the first next-generation sequencing-based companion diagnostic, for identifying patients with advanced ovarian cancer eligible for treatment with rucaparib based on detection of deleterious BRCA1 and/or BRCA2 mutations in tumor tissue. Rucaparib's approval was based primarily on efficacy data from 106 patients with BRCA mutation–associated ovarian cancer who had prior treatment with two or more chemotherapies and safety data from 377 patients with ovarian cancer treated with rucaparib 600 mg orally twice daily on two open-label, single-arm trials. Investigator-assessed objective response rate was 54% [57/106; 95% confidence interval (CI), 44–64], and median duration of response was 9.2 months (95% CI, 6.6–11.7). The approved companion diagnostic verified tumor BRCA mutation status retrospectively in 96% (64/67) of patients. Common adverse reactions (≥20%) to rucaparib were nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea. This article summarizes the FDA review and data supporting rucaparib's accelerated approval. Clin Cancer Res; 23(23); 7165–70. ©2017 AACR. See related commentary by Kohn et al., p. 7155
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Metadata
- Authors
- Balasubramaniam, S., Beaver, J. A., Horton, S., Fernandes, L. L., Tang, S., Horne, H. N., Liu, J., Liu, C., Schrieber, S. J., Yu, J., Song, P., Pierce, W., Robertson, K. J., Palmby, T. R., Chiu, H.-J., Lee, E. Y., Philip, R., Schuck, R., Charlab, R., Banerjee, A., Chen, X. H., Wang, X., Goldberg, K. B., Sridhara, R., Kim, G., & Pazdur, R.
- Venue
- Clinical Cancer Research
- Published
- 2017-11-30
- Volume
- 23
- Issue
- 23
- Pages
- 7165-7170
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2740934820
- Cited by
- 167
- References
- 1
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1337
- The paper
- Balasubramaniam, S., Beaver, J. A., Horton, S., Fernandes, L. L., Tang, S., Horne, H. N., Liu, J., Liu, C., Schrieber, S. J., Yu, J., Song, P., Pierce, W., Robertson, K. J., Palmby, T. R., Chiu, H.-J., Lee, E. Y., Philip, R., Schuck, R., Charlab, R., . . . Pazdur, R. (2017). FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.